MGTX: MeiraGTx Holdings plc Operatsion marja

MeiraGTx Holdings plc (MGTX) grafik logotipi

MeiraGTx Holdings plc (MGTX) kompaniyasining joriy operatsion marjasi uning shaxsiy gen terapiyasi ishlab chiqarish zavodlarining barqaror ishlashiga asoslangan. 44.50 ko'rsatkichi ushbu parametrning qiymatini aks ettirib, xarajatlarning samarali boshqarilishini namoyish etadi. MeiraGTx Holdings plc (MGTX) rivojlanishi ko'rlikni davolash uchun genetik nuqsonlarni tuzatishga tayanadi, moliyaviy barqarorligi esa klinik sinovlar natijalari va kapital xarajatlar nazoratiga bog'liq.

meiragtx.com (MGTX): Operatsion foyda bo'yicha sotuv rentabelligi 04.07.2022dan 20.11.2026gacha

MGTX (MeiraGTx): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Kompaniyaning fundamental baholanishi:MGTX, MeiraGTx
meiragtx.com asosiy tovari

MeiraGTx Holdings plc (MGTX) sezilarli kapital xarajatlari bilan tavsiflanuvchi yuqori texnologiyali gen terapiyasi segmentini ishlab chiqmoqda. Atrof-muhit xavfsizligi va reagentlarni utilizatsiya qilish bilan bog'liq xarajatlar sotuvlardan qolgan hisoblangan mablag'larga bevosita ta'sir qiladi. Operatsion marja foizlar va soliqlar to'lanishidan oldingi daromad ulushini o'lchaydi va asosiy jarayonlarni boshqarish samaradorligini aks ettiradi. Bu yerda past qiymatlar ko'pincha kengayish bosqichi haqida signal beradi. Operatsion marjani tahlil qilish orqali investor biznesning daromadliligini real vaqt rejimida baholaydi.

MeiraGTx Holdings plc kimlar bilan raqobatlashadi

Sotuvning operatsion marjasi TEM|QGEN - Operatsion foyda bo'yicha marjinallik|Operatsion marja IONS|RGEN - Sotuvning operatsion rentabelligi|Operatsion rentabellik Avidity RNA|Operatsion marja CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operatsion marja|Ultragenyx Pharma (RARE) - Sotuvning operatsion marjasi|beamtx.com (BEAM) - Operatsion rentabellik|SRPT: Operatsion foyda koeffitsiyenti|Sotuvning operatsion marjasi TWST|TXG - Operatsion foyda bo'yicha marjinallik|Operatsion marja NTLA|Operatsion faoliyat rentabelligi Stoke Therapeutics|Operatsion rentabellik BioLife Solutions BLFS|Wave Life Sciences (WVE) - Sotuvning operatsion rentabelligi|Maze Therapeutics, Inc. - Operatsion marja|Operatsion faoliyat rentabelligi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operatsion rentabellik|TSHA: Operatsion foyda koeffitsiyenti|Operatsion rentabellik uniQure Pharma|Sotuvning operatsion rentabelligi REGENXBIO Inc. RGNX|Operatsion rentabellik Solid Biosciences (SLDB)|Ocugen Corp - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Pacific Biosciences PACB|Operatsion foyda koeffitsiyenti BNTC (Benitec)|Design Corp - Operatsion marja|Rocket Pharmaceuticals - Operatsion foyda koeffitsiyenti|Operatsion foyda bo'yicha sotuv rentabelligi 4D Molecular Therapeutics, Inc.|Sotuvning operatsion rentabelligi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operatsion marja|Sotuvning operatsion rentabelligi Editas EDIT|Operatsion marja SLN|ProQR Therapeutics - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion marja CDXS (Codexis, Inc.)|SGMO: Operatsion foyda bo'yicha sotuv rentabelligi|Nautilus Biotechnology - Operatsion marja|Operatsion foyda normasi MGX (Metagenomi, Inc)|DTIL: Operatsion marja|GBIO: Operatsion foyda koeffitsiyenti|Operatsion rentabellik Boundless Bio Inc.|Sotuvning operatsion marjasi Exicure (XCUR)|Operatsion marja IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operatsion foyda normasi|Mustang Bio, Inc. - Sotuvning operatsion marjasi|RNAZ - Sotuvning operatsion marjasi|BNGO: Sotuvning operatsion marjasi|APDN (Applied DNA Sciences Inc) - Operatsion foyda bo'yicha sotuv rentabelligi|BLUE (Bluebird Bio) - Sotuvning operatsion marjasi|ImmunoPrecise Antibodies Ltd - Operatsion foyda normasi|OMGA (Omega Therapeutics Inc) - Operatsion marja|Operatsion rentabellik OMIC|Operatsion rentabellik Regulus Therapeutics Inc. (RGLS)|Sotuvning operatsion marjasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Sotuvning operatsion marjasi|Operatsion foyda normasi TCON|UBX - Operatsion rentabellik